The ability to differentiate human pluripotent stem cells into endothelial cells with properties of cord-blood endothelial colony-forming cells (CB-ECFCs) may enable the derivation of clinically relevant numbers of highly proliferative blood vessel-forming cells to restore endothelial function in patients with vascular disease. We describe a protocol to convert human induced pluripotent stem cells (hiPSCs) or embryonic stem cells (hESCs) into cells similar to CB-ECFCs at an efficiency of >10 8 ECFCs produced from each starting pluripotent stem cell. The CB-ECFC-like cells display a stable endothelial phenotype with high clonal proliferative potential and the capacity to form human vessels in mice and to repair the ischemic mouse retina and limb, and they lack teratoma formation potential. We identify Neuropilin-1 (NRP-1)-mediated activation of KDR signaling through VEGF 165 as a critical mechanism for the emergence and maintenance of CB-ECFC-like cells.
ECFCs, also called blood outgrowth endothelial cells [1] [2] [3] , are rare circulating endothelial cells, particularly abundant in umbilical cord blood, that display robust clonal proliferative potential and intrinsic in vivo blood vessel-forming ability [4] [5] [6] [7] . ECFCs were shown to engraft in sex-mismatched human bone marrow transplant patients, with the most proliferative ECFCs displaying genetic markings of the donor marrow 1 . Although this study proved that ECFCs are directly transplantable without an intervening period of in vitro culture, it did not fully explain the cell of origin within the donor bone marrow that gives rise to ECFCs. ECFCs have shown promise for tissue regeneration. In mouse vascular injury models, they are rapidly recruited to the site of vascular injury or tissue ischemia after intravenous injection, where they initiate a vasculogenic response 8 , and they have been reported to enhance vascular repair and improve blood flow after myocardial infarction 9 , stroke 3, 10 , ischemic retinopathy 2 and ischemic limb injury 8, 11 , and to engraft and re-endothelialize denuded vascular segments or implanted grafts 12 . In elderly patients and subjects with peripheral arterial disease (PAD) and critical limb ischemia, ECFCs may become prone to replicative senescence, reducing their reparative potential. To develop a source of CB-ECFC-like cells for vascular repair, we investigated the use of human pluripotent stem cells (hPSCs) 13, 14 , which possess virtually unlimited self-renewal capacity and the ability to differentiate into any cell type in the body.
We began by studying whether previous protocols for generating endothelial cells from hPSCs generate cells with properties of CB-ECFCs, namely, high clonal proliferative potential with selfrepopulating activity and robust in vivo vessel-forming ability 4, 6 . Several of these protocols [15] [16] [17] [18] [19] [20] relied on co-culture with OP9 stromal cells 16, 20 or embryoid body formation 15, 18, 19 followed by application of various growth factors and/or receptor signaling pathway inhibitors to promote endothelial cell differentiation. However, the derived endothelial cells are in some cases unstable, drifting to various nonendothelial phenotypes 21 , or exhibit low proliferative potential with a tendency to reach replicative senescence within 5-7 passages 18, 19, 21 . We found that cells derived through co-culture with OP9 cells 16 or through embryoid body formation 15 do not have the specific characteristics of CB-ECFCs ( Supplementary  Figs. 1 and 2 ).
Next, we tested a more recent two-step endothelial-differentiation protocol that involves initial embryoid body formation and then twodimensional (2D) adherent cell culture with added growth factors and a TGFβ inhibitor 17 (Supplementary Fig. 3 ). Whereas this paper studied CD144 + cells, we undertook a more directed search for precursors of CB-ECFCs by looking for other specific markers of endothelial cells in the cultures of differentiating cells. Undifferentiated human pluripotent stem cells express the endothelial marker VEGF receptor 2 (KDR) but not the endothelial markers NRP-1 and CD31. NRP-1 is expressed before CD31, CD34 and CD144 during endothelial lineage differentiation 15 and has a well-established role in cardiovascular Differentiation of human pluripotent stem cells to cells similar to cord-blood endothelial colony-forming cells 1 1 5 2 VOLUME 32 NUMBER 11 NOVEMBER 2014 nature biotechnology l e t t e r s development and angiogenesis 22 . Using the protocol of reference 17, we found that only NRP-1 + CD31 + cells exhibited high clonal proliferative potential and in vivo vessel-forming ability in the continuous presence of TGFβ inhibition during both differentiation and maintenance (Supplementary Fig. 3) . However, as shown previously 17, 21 , endothelial cells derived by this protocol became unstable and lost high clonal proliferative potential and in vivo vessel-forming ability soon after TGFβ inhibition was removed (data not shown).
To develop a protocol for generating NRP-1 + CD31 + cells with CB-ECFC properties that does not require embryoid body formation, co-culture with OP9 cells or TGF-β inhibition, we focused on generating different mesoderm subsets. Human pluripotent cells were cultured in 2D adherent cell culture with added growth factors in a serum-free culture condition (Fig. 1a) . As Activin-A, BMP-4, FGF-2 and VEGF are critical for the emergence of mesoderm cells and the specification of endothelial cells from mesoderm cells 17, 23 , we optimized the concentrations of these factors compared with previous protocols. A combination of these factors at a concentration of 10 ng/ml allowed us to enhance and isolate NRP-1 + CD31 + cells capable of giving rise to stable CB-ECFC-like cells with clonal proliferative potential and in vivo vessel-forming capacity in the absence of TGFβ inhibition. npg l e t t e r s NRP-1 + CD31 + cells gave rise to significantly more endothelial colonies than NRP-1 − CD31 + cells (P < 0.001; Fig. 1b) . NRP-1 + CD31 + progeny were homogenous and displayed a cobblestone appearance (Fig. 1) . A significant (15-fold) increase in total cell number was counted in 7-day expansion cultures initiated with NRP-1 + CD31 + cells compared to NRP-1 − CD31 + cells (P < 0.001; Fig. 1b) . Further, cells grown from the NRP-1 + CD31 + fraction exhibited surface co-expression of NRP-1 and CD31 (Fig. 1d) and uniform expression of CD144, but lacked expression of the mesenchymal marker α-SMA (Fig. 1d) . Only 2% of the NRP-1 + CD31 + cell subset failed to divide, and 48% formed high proliferative potential-ECFCs (HPP-ECFCs) (defined as single cell-derived colonies with >2,000 progeny that contain selfrenewing clonal HPP-ECFC activity) ( Fig. 1e and Supplementary  Fig. 4e ) with a colony cell number distribution very similar to that of CB-ECFCs (Fig. 1e) . Furthermore, NRP-1 + CD31 + cells formed highly branching capillary structures (Fig. 1f) . NRP-1 + CD31 + cells produced endothelial cells with robust in vivo vessel-forming ability; the vessels inosculated with host mouse vessels (Fig. 1f,g ), similar to CB-ECFCs previously described 4, 7 . Notably, the NRP-1 + CD31 + cells did not form teratomas after >6 months of implantation into immunodeficient mice (n = 24 animals; data not shown). Thus, hESC-and hiPSC-derived NRP-1 + CD31 + cells displayed properties of ECFCs similar to CB-ECFCs and will be referred to hereafter as hESC-ECFCs or hiPSC-ECFCs or, when discussing results derived from both, hPSC-ECFCs. hPSC-derived NRP-1 − CD31 + cells did not show these properties ( Supplementary Fig. 4) .
We used two additional models to test the endothelial function of hiPSC-ECFCs, in addition to our subcutaneous implant method. We compared three study groups: (i) hiPSC-ECFCs, (ii) hiPSC-embryoid body-derived TGFβ-inhibited CD144 + endothelial cells (hiPSC-EBT-CD144 + ECs) 17 and (iii) CB-ECFCs 4, 6 . Although we sought to test a fourth study group, we were unable to derive enough hiPSCembryoid body-derived KDR + NRP-1 + endothelial cells to perform these comparative studies.
In the first model, we measured rescue of blood vessel formation and reduction of neovascular tufts in newborn mice exposed to high oxygen concentration 2 . The oxygen-induced retinopathy (OIR) in the neonatal pups results from hypoxia-induced loss of retinal vessels followed by an overexuberant retinal hypoxic response. A significant reduction of the post-injury avascular area occurred in retinas that npg l e t t e r s received hiPSC-ECFCs (≥36% reduction; **P < 0.01) but not in retinas that received hiPSC-EBT-CD144 + ECs (≤14% reduction in avascular area; P = not significant (ns)) (Fig. 2a,b) . In addition, only hiPSCECFCs significantly reduced preretinal neovascular tufts ( Fig. 2c ; hiPSC-EBT-CD144 + EC results not shown). Prelabeling of the cells with Qdots 655 and imaging at 72 h after cell delivery showed that hiPSC-ECFCs integrated in higher numbers and with wider distribution in host retinal tissue compared with hiPSC-EBT-CD144 + ECs (Supplementary Fig. 5a ). The hiPSC-ECFCs but not the hiPSC-EBT-CD144 + ECs also appeared to form vascular tube structures in the superficial retinal plexus (Supplementary Fig. 5b ).
We also studied a model of hind limb femoral vessel removal in nude mice 24 . Salvage of ischemic limbs and blood flow were significantly improved by hiPSC-ECFCs compared with hiPSC-EBT-CD144 + ECs (P < 0.05; Fig. 2d-f and data not shown). In these assays, hiPSC-ECFCs functioned similarly to CB-ECFCs.
Primary cells do not proliferate indefinitely but instead undergo senescence after long-term in vitro culture 25 . We could expand both hPSC-ECFCs and CB-ECFCs up to passage 18 (P18) without loss of typical endothelial cell features (Supplementary Fig. 6a-c) . Notably, although the majority of P18 hPSC-ECFCs and CB-ECFCs were senescent and exhibited characteristics of mortal primary cells 25 , they still maintained an endothelial cobblestone morphology and expression of endothelial antigens CD31, NRP-1 and CD144, but not α-SMA (Supplementary Fig. 6d) . Thus, hPSC-ECFCs maintained a stable endothelial phenotype throughout long-term expansion culture but, like any primary cell type, eventually exhibited replicative senescence.
To compare the various ECFC subsets at the transcriptional level, we performed whole-transcriptome sequencing (RNA-seq) analysis on undifferentiated hiPSCs (hiPSC-day 0), day 3 differentiated hiPSCs (hiPSC-day 3), day 12 hiPSC-ECFCs, day 12 hESC-ECFCs and CB-ECFCs, as previously described 21 . Notably, both hiPSC-and hESC-ECFCs exhibited decreased expression of pluripotent and nonendothelial lineage-specific gene transcripts but increased expression of endothelial gene transcripts (Supplementary Fig. 7a,b) , similar to CB-ECFCs.
We investigated an approach for enhancing the generation of hPSC-ECFCs. KDR has a well-established role in endothelial specification and maintenance, but it is unknown whether NRP-1 enhances KDR activation in hiPSCs undergoing ECFC lineage differentiation and increases the generation of stable ECFCs. It has been proposed that NRP-1 on the endothelial cell surface binds to VEGF 165 as a co-receptor with KDR 22 . Formation of NRP-1-VEGF 165 -KDR signaling complexes enhances VEGF-KDR-mediated signaling activity and biological function 22, 26, 27 . NRP-1 has also been clearly shown to be required for maximum KDR activity and/or KDR tyrosine phosphorylation 22, 26, 27 , and to selectively mediate VEGF-KDR signaling through p130 Cas /Pyk2 activation in endothelial cells 22 . To study whether increasing NRP-1 activity would enhance KDR activation and the generation of hPSC-ECFCs, we screened for and identified the mesoderm subset with robust KDR expression and the first evidence of NRP-1 expression, which emerged on day 6 of hPSC differentiation (inset, Fig. 3b) . We modulated NRP-1 expression in these cells with dimeric Fc-NRP-1, a surrogate for membrane NRP-1 (ref. 28) , which enhances NRP-1 activity, or the monoclonal antibody, NRP-1-B 27 , which blocks NRP-1 activity. Dose-response experiments identified a specific dose (3.3 nM for Fc-NRP-1 dimer and 500 ng/ml for NRP-1-B) and length of time (4-6 d) for the treatment that gave reproducible results (data not shown and Fig. 3a) as reported 27, 28 . After 4 d of treatment, Fc-NRP-1 dimer significantly increased (P < 0.01) and NRP-1-B significantly diminished (P < 0.001) generation of NRP-1 + CD31 + cells (Fig. 3b) . Fc-NRP-1 dimer treatment also increased activation of KDR and of p130 Cas , a downstream molecule activated by NRP-1-mediated activation of KDR 22 (Fig. 3c and  Supplementary Fig. 8) . In contrast, NRP-1-B-treated cells displayed npg l e t t e r s decreased KDR phosphorylation and reduced activation of downstream molecules ( Fig. 3c and Supplementary Fig. 8 ). These data suggest that NRP-1 enhanced the generation of ECFCs from human pluripotent stem cells by potentiating KDR signaling.
Next, we asked whether NRP-1 is also involved in the maintenance of the proliferative potential of cultured ECFCs. NRP-1 expression was progressively downregulated in late-passage hPSC-ECFCs, and low levels of NRP-1 expression in late ECFCs were associated with c npg l e t t e r s decreased total proliferative potential (Fig. 4a,b) . In late-passage (P14) hPSC-ECFCs, KDR was expressed in 50-60% of cells (Fig. 4c) . However, when cultured in the presence of Fc-NRP-1 for 7 d, P14 hPSC-ECFCs displayed significantly increased (P < 0.001) expansion (Fig. 4d) but decreased β-galactosidase expression (senescence marker) compared to control and NRP-1-B-treated groups (Fig. 4e,f) . Fc-NRP-1-treated P14 hPSC-ECFCs also displayed a significant decrease in the percentage of pro-apoptotic cells compared to control treated (P < 0.01) cells (Fig. 4g) . Furthermore, the effects of Fc-NRP-1 on KDR activation were dependent upon the presence of VEGF 165 , as VEGF 121 did not promote interaction between Fc-NRP-1 and KDRpositive P14 hPSC-ECFC (Fig. 4g-i) . Thus, Fc-NRP-1 activation of KDR by VEGF 165 contributes to the rescue of proliferation and the reduction of expression of senescence markers and of pro-apoptotic behavior in near-senescent hPSC-ECFCs. Finally, preliminary studies showed that circulating and resident arterial-derived primary endothelial cells derived from patients with PAD and critical limb ischemia exhibited low levels of NRP-1 expression, possessed low clonal proliferative potential, exhibited markers of senescence and did not form robust in vivo human vessels upon implantation in immunodeficient mice ( Supplementary  Fig. 9a-g ). However, Fc-NRP-1 treatment facilitated proliferation, survival and modestly diminished evidence of senescence in these cells (Supplementary Fig. 9h-n) . Thus, Fc-NRP-1 treatment of latepassage, near-senescent hiPSC-ECFCs and patient-derived PAD-ECs increases proliferative potential, decreases apoptosis and diminishes markers of senescence in a VEGF 165 -dependent fashion.
In this study we have established a method to reproducibly derive and isolate a homogenous and stable population of pluripotent stem cell-derived endothelial cells possessing CB-ECFC properties: formation of a homogenous monolayer with characteristic cobblestone appearance, high clonal proliferative potential, formation of capillary structures when cultured on Matrigel and generation of robust in vivo-inosculated vessels after implantation in immunedeficient mice. By assaying for specific CB-ECFC properties rather than simply relying on classical cell surface expression of 'endothelial' markers or gene expression patterns, we derived ECFCs that we did not detect among the endothelial cells derived by previous methods [15] [16] [17] . The hiPSC-ECFCs significantly contributed to vascular repair of experimentally induced ischemic limbs and hyperoxic injured retinas in murine models, similar to CB-ECFCs, and were superior to endothelial cells isolated using other published protocols [15] [16] [17] . They were stable and did not transition to nonendothelial cells over prolonged culture (18 passages) and could expand to over a trillion endothelial cells in less than 3 months (Fig. 1a) . This efficient output of functional endothelial cells contrasts with previous reported yields of 0.6 (ref. We also found that NRP-1-VEGF 165 -KDR-mediated activation of KDR is a critical mechanism both for derivation of hPSC-ECFCs and for enhancing survival and proliferative potential of late-passage, nearsenescent hPSC-ECFCs and patient-derived ECFCs. Our results may enable highly efficient production of patient-derived ECFCs for the treatment of cardiovascular disease.
METhoDS
Methods and any associated references are available in the online version of the paper.
oNLINE METhoDS
Culturing of hESCs and hiPSCs. hESC line H9 (ref. 13 ) and fibroblast-derived human iPSC line (DF19-9-11T) 14 were purchased from WiCell Research institute (Madison, Wisconsin). Several other hiPSC lines (FCB-iPS-1 and FCB-iPS-2) derived in the Broxmeyer and Yoder laboratories were also used to generate ECFCs 30, 31 (Supplementary Table 1 ). Both hESCs and hiPSCs were maintained in mTeSR1 complete media (Stem Cell Technologies) on Matrigel in 10 cm 2 tissue culture dishes at 37 °C and 5% CO 2 . After the plating of cells, media was changed on days 2, 3 and 4. Cells were passaged on day 5. Media was aspirated and 4-5 ml of dispase (2 mg/ml, Gibco) containing media was added to the plate and incubated at 37 °C for 3-5 min or until the edges of the colonies had lifted from the plate. Dispase containing media was aspirated from the plate and cells were gently washed with DMEM-F12 (Gibco) three times to remove any residual amount of enzyme. Fresh media was then used to collect colonies from the plate using a forceful wash and scraping with a 5-ml disposable pipette taking care to avoid bubbles. Collected colonies were then centrifuged at 300 g for 5 min. The supernatant was aspirated and pellet was resuspended in mTeSR1 complete media. Prior to passaging, 10 cm 2 tissue culture dishes were coated with Matrigel for 30 min. Unattached Matrigel was removed from the tissue culture dishes and 7 ml of mTeSR1 complete medium was added to dishes. Colonies evenly distributed in mTeSR1 media were added to each plate. Cells were then spread out within the dish using multiple side-to-side shaking motions while avoiding any swirling. Cultures were checked for growth quality and morphology, and by performing teratoma formation assay as previously described 31 .
Directed differentiation of hESCs and hiPSCs into the ECFC lineage.
After 2 d (-D2) of culture in mTeSR1 media, cultures were directed toward the mesodermal lineage with addition of activin A (10 ng/ml) in the presence of FGF-2, VEGF 165 and BMP4 (10 ng/ml) for 24 h. The following day, activin-A containing media was removed and replaced with 8 ml of Stemline II complete media (Sigma) containing FGF-2 (Stemgent), VEGF 165 (R&D) and BMP4 (R&D) to promote endothelial cell emergence and expansion. Media was replaced with 8 ml of fresh Stemline II differentiation media on days 3, 5, 7 and 8. On day 9 and thereafter media was changed with 10 ml of Stemline II differentiation media.
Flow cytometry. At day 12 after differentiation, adherent cells were harvested using TrypleE and made into a single-cell suspension in EGM-2 medium. Cells were counted and aliquots of the cell suspension were prepared for antibody staining. FcR blocking reagent (Miltenyi Biotech) was added to prevent the nonspecific binding of antibodies. Anti-human CD31 (CD31-FITC, clone WM59 from BD Pharmingen), CD144 (CD144-PE, clone 16B1 from eBioscience) and NRP-1 (NRP-1-APC, clone AD5-176 from Miltenyi Biotech) antibodies were used at concentrations that were titrated before use (Supplementary Table 2 ). Propidium iodide (PI, Sigma) was added to the cell suspension for dead cell staining. Flow cytometric detection of the cell surface antigens and cells sorting were performed on an LSR II and FACSAria (Becton Dickinson), respectively. Compensation was set by single-positive controls using cord blood-derived ECFCs. A gating of targeted cell population was determined based on fluorescent minus one (FMO) controls for each fluorescent color.
Cell culture of sorted cells. CD31 + -, CD144 + -or KDR + -and NRP-1 + -sorted cells were centrifuged at 300 g for 5 min then resuspended in 50% EGM-2 and 50% complete Stemline II differentiation media. To generate ECFCs from the sorted population, 2,500 cells per well were seeded on rat tail type I collagen-coated 12-well plates. After 2 d, the media was aspirated and three parts of EGM-2 and one part of differentiation media was added to the cultures. ECFC colonies appeared as tightly adherent cells and exhibited cobblestone morphology on day 7. On occasion, cloning cylinders were used to isolate ECFC colonies from heterogeneous cell populations. Cloning of endothelial cell clusters was performed to isolate pure populations of highly proliferative endothelial cells as described previously 4, 5 . Confluent ECFCs were passaged by plating 10,000 cells per cm 2 as a seeding density and ECFCs were maintained in complete endothelial growth media (collagen coated plates and cEGM-2 media) with media change every other day as described previously 4, 5 .
In vitro capillary network formation assay on Matrigel. Endothelial cells derived from different protocols were trypsinized and resuspended in EGM-2 media. Cells were plated at a density of 1.0 × 10 4 cells per well in triplicate in 96-well plates coated with 50 µl of growth factor-reduced Matrigel (BD Biosciences). Plates were incubated overnight at 37 °C. After 8-16 h of incubation, photomicrographs were taken from each well at 10× magnification using a Zeiss Axiovert 25 CFL inverted microscope with a 10× CP-ACHROMAT/0.12 NA objective. Images were acquired using a SPOT RT color camera (Diagnostic Instruments) with the manufacturer's software. Phase contrast images were taken with air objectives.
Immunochemistry. ECFCs were fixed with 4% (w/v) paraformaldehyde for 30 min and permeabilized with 0.1% (v/v) Triton X-100 in PBS for 5 min. After blocking with 10% (v/v) goat serum for 30 min, cells were incubated with primary following antibodies; anti-CD31 (Santa Cruz), anti-CD144 (Ebioscience), anti-NRP-1 (Santa Cruz) and anti-a-SMA, (Chemicon) overnight at 4 °C. Cells were washed with PBS, then incubated with secondary antibodies conjugated with Alexa-488 or Alexa-565 (Molecular Probe) and visualized by confocal microscopy after counterstaining with 2 g/ml DAPI (Sigma-Aldrich). The confocal images were obtained with an Olympus FV1000 mpE confocal microscope using as an Olympus uplanSApo 60xW/1.2NA/eus objective. All the images were taken as Z-stacks with individual 10-µm thick sections at room temperature and images were analyzed using FV10-ASW 3.0 Viewer.
Single-cell assay. CB-ECFCs or iPSC-ECFCs or hESC-ECFCs or hiPSC-EBT-CD144 + ECs and PAD-derived ECs were subjected to a single-cell assay to evaluate clonogenic proliferative potential. Briefly, endothelial cells were treated with trypLE Express (Invitrogen) to obtain a single-cell suspension. Cell counts and serial dilutions were performed to obtain a concentration of 0.68 cells per well in individual wells of 96-well culture plates. Wells were examined the day after plating to ensure the presence of a single cell per well. Culture media was changed on days 4, 8 and 12. On day 14 of culture, cells were stained with Sytox reagent (Invitrogen), and each well was examined to quantitate the number of cells using a fluorescent microscope. Those wells containing two or more cells were identified as positive for proliferation under a fluorescent microscope at 10× magnification using a Zeiss Axiovert 25 CFL inverted microscope with a 10 × CP-ACHROMAT/0.12 NA objective. Wells with endothelial cell counts of 2-50, 51-500, 501-2,000 and ≥2,001 were labeled as endothelial cell clusters (ECCs), low proliferative potential ECFCs (LPP) and high proliferative potential ECFCs (HPP), as previously described 4, 5 .
Cell viability, senescence and cell proliferation assay. Endothelial cells were plated at a density of 5 × 10 4 per well or 1 × 10 5 per well on type I collagencoated 12-well and 6-well plates, respectively. After 24 h, growth media was replaced with Fc-control, Fc-NRP-1 dimer (R&D Systems) or NRP-1 blocking antibodies containing EGM-2 medium for 7 d and media was replaced on every alternative day. NRP-1A and NRP-1B antibodies were generously provided by Genentech 27 . Cell viability and proliferation was assessed by Trypan blue exclusion, and the numbers of dye-free cells were counted under a phase microscope in triplicate per condition.
A senescence assay kit was purchased from Biovision, and the assay performed according to the manufacturer's instructions. Briefly, endothelial cells were seeded onto 12-well plates for overnight culture to form a monolayer. The following day, cells were fixed in 0.5 ml of the commercial fixative solution for 10-15 min at room temperature. Cells were washed twice with 1 ml of 1× PBS and stained with 0.5 ml of the commercial staining solution for overnight at 37 °C. Cells were observed under a microscope for development of a blue color. Photomicrographs were taken from each well at 10× magnification using a Zeiss Axiovert 25 CFL inverted microscope with a 10× CP-ACHROMAT/0.12 NA objective. Images were acquired using a SPOT RT color camera (Diagnostic Instruments) with the manufacturer's software. Phase contrast images were taken with air objectives.
Mice. All animal procedures were carried in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional npg quality was examined as previously described 21 . RNA sequence library was generated using 1 µg of high-quality total RNA and sequencing was performed using Illumina HiSeq2000 sequencer as previously described 21 . The resulting sequence reads were mapped to the human genome (hg18) using TopHat with default parameters, and the RefSeq (June 2010) transcript levels (FPKMs) were quantified using CuffLinks. Heatmaps of select transcripts were then plotted using red-to-green scale using R statistical software package of heatmap.2 from RNA-seq data.
Statistical analysis.
All experiments were performed ≥3 times in triplicate and data are represented as mean value ± s.d. for statistical comparison. A power of analysis with a 95% confidence interval was used to calculate sample size required to obtain statistically significant results. The sampling number we used gave a normal distribution. Significance of differences was assessed by a two-tailed Student's t-test or one way ANOVA-Tukey post-hoc test Multiple Comparison Test or chi-squared test.
